Wang Li, Ji Feng, Liu Gang, Wang Wei, Li Zhitong, Yue Yongqiang, Wang Zhonggao
Department of Interventional Radiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China,
Department of Center for Clinical Single Cell Biomedicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou 450003, China.
Onco Targets Ther. 2018 Dec 17;12:1-7. doi: 10.2147/OTT.S162603. eCollection 2019.
Barrett's esophagus (BE) is one of the major known risk factors for esophageal adenocarcinoma (EAC). Circulating miRNAs are emerging as predictive biomarkers for early detection of malignancy. However, the potential for circulating miRNAs to be used as biomarkers for BE neoplastic progression to EAC has not been well characterized.
We performed a systematic screening approach to identify spectrum miRNAs in the serum of both BE and EAC patients.
miRNA-array web-based software identified 116 sequences differentially expressed between BE patients and healthy controls. Subsequent study revealed that miR130a was significantly upregulated in serum samples of BE and EAC patients compared to healthy controls. We found an increase in serum miR130a in low-grade and high-grade dysplasia BE patients compared to individuals with metaplasia. We also observed that miR130a expression levels increased gradually from early-stage (I, II) to advanced-stage (III, IV) EAC patients.
Our preliminary results provide evidence that circulating miR130a is correlated with the development of BE and EAC.
巴雷特食管(BE)是已知的食管腺癌(EAC)主要危险因素之一。循环微RNA正逐渐成为恶性肿瘤早期检测的预测生物标志物。然而,循环微RNA作为BE向EAC肿瘤进展生物标志物的潜力尚未得到充分表征。
我们采用系统筛选方法来鉴定BE和EAC患者血清中的微RNA谱。
基于微RNA阵列的网络软件鉴定出BE患者与健康对照之间有116个序列差异表达。后续研究表明,与健康对照相比,BE和EAC患者血清样本中的miR130a显著上调。我们发现,与化生个体相比,低级别和高级别发育异常BE患者血清中的miR130a增加。我们还观察到,从早期(I、II期)到晚期(III、IV期)EAC患者,miR130a表达水平逐渐升高。
我们的初步结果提供了证据,表明循环miR130a与BE和EAC的发生相关。